Contact Us
© 2017 Pharmstandard Ventures

Latest News

Fund's News and Porfolio Companies' News

Latest News

Fund's News and Porfolio Companies' News
28.09.2018

Upcoming Events – 4Q 2018
26.03.2018

Upcoming Events – 2Q 2018
21.11.2024
TearSolutions, Inc. Secures $3M Series B Funding
21.10.2024
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
09.09.2024
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
09.09.2024
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
05.04.2024
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
05.04.2024
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
30.11.2023
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
01.11.2023
TearSolutions, Inc. Appoints Robert Dempsey to its Board of Directors
23.10.2023
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
20.09.2023
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
12.07.2023
Liminal BioSciences Announces Arrangement Agreement with S
02.06.2023
Liminal BioSciences Provides R&D Update
15.05.2023
Protara Therapeutics Announces Dosing of First Patients in Pha
02.05.2023
Protara Therapeutics Receives Regulatory Clearance from FDA t
28.04.2023
Protara Therapeutics Announces Positive Preliminary Data fro
05.04.2023
Liminal Biosciences Confirms Receipt of Unsolicited Non-Bindin
30.01.2023
Protara Therapeutics Announces Appointment of Patrick Fabbi
26.01.2023
Liminal BioSciences Announces Reverse Stock Split
06.01.2023
Liminal BioSciences Announces Priorities For 2023
01.12.2022
Protara Therapeutics Announces Trials in Progress Poster Prese
19.07.2022
Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease
12.07.2022
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split
26.05.2022
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
23.05.2022
Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras
14.05.2022
Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras
12.05.2022
Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
04.05.2022
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering
24.03.2022
Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
07.03.2022
Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
16.02.2022
Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP
19.01.2022
Liminal BioSciences Announces Strategic Priorities For 2022
10.01.2022
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
04.01.2022
Allena Pharmaceuticals Provides Clinical and Corporate Update
03.11.2021
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease
15.10.2021
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business
12.10.2021
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
07.10.2021
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
29.09.2021
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346
15.09.2021
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
13.09.2021
Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
13.07.2021
Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12.07.2021
Allena Pharmaceuticals Provides Update on Clinical Development Programs
23.06.2021
Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day
15.06.2021
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
10.06.2021
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
08.06.2021
Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease
04.06.2021
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
23.04.2021
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations
19.04.2021
Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer
12.04.2021
Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
10.04.2021
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
07.04.2021
Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors
12.03.2021
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
09.03.2021
Jounce Therapeutics Announces Proposed Offering of Common Stock
09.03.2021
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
12.02.2021
Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine
12.02.2021
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
02.02.2021
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
29.01.2021
Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science
25.01.2021
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
13.01.2021
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064
29.12.2020
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY
23.12.2020
TransMedics Appoints Merilee Raines to Board of Directors
21.12.2020
Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
16.12.2020
Jounce Therapeutics Added to NASDAQ Biotechnology Index
15.12.2020
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
14.12.2020
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
11.12.2020
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
09.12.2020
Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
07.12.2020
Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
02.12.2020
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
02.12.2020
Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer
01.12.2020
Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
01.12.2020
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million
01.12.2020
Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering
01.12.2020
Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer
30.11.2020
Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346
28.11.2020
TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting
20.11.2020
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
18.11.2020
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
16.11.2020
BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candidate BNT162b2 trial in China
16.11.2020
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
11.11.2020
Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
11.11.2020
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting
09.11.2020
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
09.11.2020
Pfizer Canada and BioNTech Initiate Rolling Submission to Health Canada for SARS-CoV-2 Vaccine Candidate BNT162b2
08.11.2020
Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim® (plasminogen) BLA
05.11.2020
Allena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of Directors
02.11.2020
Jounce Therapeutics Announces Update on Vopratelimab Program
30.11.2020
Liminal BioSciences Announces Private Placement Financing of USD$30 Million
06.11.2020
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
30.09.2020
Allena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
22.09.2020
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
21.09.2020
Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)
21.09.2020
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
17.09.2020
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
15.09.2020
BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162
12.09.2020
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
09.09.2020
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
08.09.2020
Biopharma Leaders Unite to Stand with Science
08.09.2020
Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease
08.09.2020
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications
07.09.2020
BioNTech and Pfizer Receive Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial for COVID-19 Vaccine Candidate BNT162b2
01.09.2020
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
27.08.2020
BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech's BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR
20.08.2020
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
12.08.2020
Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature
05.08.2020
Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
05.08.2020
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
31.07.2020
Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
31.07.2020
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
30.07.2020
BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature
28.07.2020
Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
27.07.2020
Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
27.07.2020
BioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares
27.07.2020
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million
27.07.2020
Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering
27.07.2020
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
22.07.2020
BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering
22.07.2020
Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
21.07.2020
BioNTech Announces Proposed Public Offerings
20.07.2020
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
20.07.2020
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
13.07.2020
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
01.07.2020
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
29.06.2020
BioNTech to Raise USD 250 Million in Private Placement
22.06.2020
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting
11.06.2020
European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing
04.06.2020
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
03.06.2020
Allena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
26.05.2020
TransMedics Announces Pricing of Public Offering of Common Stock
26.05.2020
TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS™ Liver PROTECT Trial
26.05.2020
Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
12.05.2020
Protagonist Therapeutics, Inc. Announces Upsizing and Pricing of Underwritten Public Offering of 7,000,000 Shares of Common Stock
11.05.2020
ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics
11.05.2020
Protagonist Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Common Stock
07.05.2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
06.05.2020
BioNTech Completes Acquisition of Neon Therapeutics
05.05.2020
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
13.04.2020
TransMedics Provides COVID-19 Pandemic Update and Announces Preliminary Financial Results for First Quarter 2020
17.03.2020
TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting Due to COVID-19 Emergency
26.02.2020
Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020
12.02.2020
Allena Pharmaceuticals Announces Streamlined Design for URIROX-2
11.02.2020
ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer
06.02.2020
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data
23.01.2020
Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors
16.01.2020
BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
10.01.2020
ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics
08.01.2020
enGene Announces Additions to Senior Management Team
07.01.2020
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
06.01.2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
19.07.2022
Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease
12.07.2022
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split
26.05.2022
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
23.05.2022
Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras
14.05.2022
Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras
12.05.2022
Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
04.05.2022
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering
24.03.2022
Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
07.03.2022
Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
16.02.2022
Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP
19.01.2022
Liminal BioSciences Announces Strategic Priorities For 2022
10.01.2022
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
04.01.2022
Allena Pharmaceuticals Provides Clinical and Corporate Update
03.11.2021
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease
15.10.2021
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business
12.10.2021
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
07.10.2021
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
29.09.2021
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346
15.09.2021
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
13.09.2021
Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
13.07.2021
Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12.07.2021
Allena Pharmaceuticals Provides Update on Clinical Development Programs
23.06.2021
Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day
15.06.2021
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
10.06.2021
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
08.06.2021
Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease
04.06.2021
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
23.04.2021
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations
19.04.2021
Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer
12.04.2021
Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
10.04.2021
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
07.04.2021
Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors
12.03.2021
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
09.03.2021
Jounce Therapeutics Announces Proposed Offering of Common Stock
09.03.2021
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
12.02.2021
Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine
12.02.2021
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
02.02.2021
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
29.01.2021
Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science
25.01.2021
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
13.01.2021
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064
29.12.2020
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY
23.12.2020
TransMedics Appoints Merilee Raines to Board of Directors
21.12.2020
Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
16.12.2020
Jounce Therapeutics Added to NASDAQ Biotechnology Index
15.12.2020
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
14.12.2020
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
11.12.2020
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
09.12.2020
Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
07.12.2020
Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
02.12.2020
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
02.12.2020
Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer
01.12.2020
Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
01.12.2020
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million
01.12.2020
Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering
01.12.2020
Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer
30.11.2020
Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346
28.11.2020
TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting
20.11.2020
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
18.11.2020
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
16.11.2020
BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candidate BNT162b2 trial in China
16.11.2020
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
11.11.2020
Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
11.11.2020
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting
09.11.2020
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
09.11.2020
Pfizer Canada and BioNTech Initiate Rolling Submission to Health Canada for SARS-CoV-2 Vaccine Candidate BNT162b2
08.11.2020
Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim® (plasminogen) BLA
05.11.2020
Allena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of Directors
02.11.2020
Jounce Therapeutics Announces Update on Vopratelimab Program
30.11.2020
Liminal BioSciences Announces Private Placement Financing of USD$30 Million
06.11.2020
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
30.09.2020
Allena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
22.09.2020
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
21.09.2020
Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)
21.09.2020
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
17.09.2020
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
15.09.2020
BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162
12.09.2020
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
09.09.2020
Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
09.09.2020
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
08.09.2020
Biopharma Leaders Unite to Stand with Science
08.09.2020
Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease
08.09.2020
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications
07.09.2020
BioNTech and Pfizer Receive Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial for COVID-19 Vaccine Candidate BNT162b2
01.09.2020
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
27.08.2020
BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech's BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR
20.08.2020
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
12.08.2020
Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature
05.08.2020
Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
05.08.2020
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
31.07.2020
Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
31.07.2020
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
30.07.2020
BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature
28.07.2020
Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
27.07.2020
Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
27.07.2020
BioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares
27.07.2020
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million
27.07.2020
Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering
27.07.2020
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
22.07.2020
BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering
22.07.2020
Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
21.07.2020
BioNTech Announces Proposed Public Offerings
20.07.2020
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
20.07.2020
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
13.07.2020
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
01.07.2020
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
29.06.2020
BioNTech to Raise USD 250 Million in Private Placement
22.06.2020
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting
11.06.2020
European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing
04.06.2020
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
03.06.2020
Allena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
26.05.2020
TransMedics Announces Pricing of Public Offering of Common Stock
26.05.2020
TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS™ Liver PROTECT Trial
26.05.2020
Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
12.05.2020
Protagonist Therapeutics, Inc. Announces Upsizing and Pricing of Underwritten Public Offering of 7,000,000 Shares of Common Stock
11.05.2020
ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics
11.05.2020
Protagonist Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Common Stock
07.05.2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
06.05.2020
BioNTech Completes Acquisition of Neon Therapeutics
05.05.2020
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
13.04.2020
TransMedics Provides COVID-19 Pandemic Update and Announces Preliminary Financial Results for First Quarter 2020
17.03.2020
TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting Due to COVID-19 Emergency
26.02.2020
Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020
12.02.2020
Allena Pharmaceuticals Announces Streamlined Design for URIROX-2
11.02.2020
ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer
06.02.2020
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data
23.01.2020
Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors
16.01.2020
BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
10.01.2020
ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics
08.01.2020
enGene Announces Additions to Senior Management Team
07.01.2020
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
06.01.2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
You can see older news in the news Archive section